Tag: Nonmerger

Displaying 1 - 20 of 407 results.

Pages

After Chief Administrative Law Judge D. Michael Chappell held in his Initial Decision that two of three respondents named in a Federal Trade Commission complaint violated U.S. antitrust laws, those companies have declined to appeal the decision to the federal district court.
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that a Texas company providing therapist staffing services to home health agencies, its owner, and the former owner of a competitor agreed to reduce pay rates for therapists and invited other...
In The Wizard of Oz, Dorothy was told to ignore the man behind the curtain. Some may argue that the same guidance applies to ancillary parts of a merger or joint venture agreement. These can include non-solicitation and non-compete provisions. Even when such provisions are ancillary...
Reckitt Benckiser Group plc has agreed to pay $50 million to settle Federal Trade Commission charges that it violated the antitrust laws through a deceptive scheme to thwart lower-priced generic competition to its branded drug Suboxone. Suboxone is a prescription oral medication used to minimize...
Federal Trade Commission Bureau of Competition Director Bruce Hoffman issued this statement regarding the U.S. District Court for the Northern District of California’s ruling yesterday that Qualcomm Inc.’s licensing practices relating to its modem chips violate Sections 1 and 2 of the Sherman Act...
The Federal Trade Commission sued the health information company Surescripts, alleging that the company employed illegal vertical and horizontal restraints in order to maintain its monopolies over two electronic prescribing, or “e-prescribing,” markets: routing and eligibility.
The FTC sued the health information company Surescripts, alleging that the company employed illegal vertical and horizontal restraints in order to maintain its monopolies over two electronic prescribing, or “e-prescribing,” markets: routing and eligibility.  According to the complaint...
The Federal Trade Commission has reached a settlement in FTC v. Actavis, the 2009 FTC case alleging that the brand-name drug company Solvay and three generic drug companies illegally agreed to restrict generic competition to Solvay’s branded testosterone-replacement drug AndroGel for nine years.
The Federal Trade Commission has reached a global settlement resolving pending claims in three separate federal court antitrust lawsuits involving subsidiaries of pharmaceutical manufacturer Teva Pharmaceuticals Industries Ltd. If approved by the various courts, the stipulated order will prohibit...

Pages